FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2922140624> ?p ?o ?g. }

• W2922140624 abstract "Resistance to immune checkpoint inhibitors (ICIs) has been linked to local immunosuppression independent of major ICI targets (e.g., PD-1). Clinical experience with response prediction based on PD-L1 expression suggests that other factors influence sensitivity to ICIs in non-small cell lung cancer (NSCLC) patients.Tumor specimens from 120 NSCLC patients from 10 institutions were evaluated for PD-L1 expression by immunohistochemistry, and global proliferative profile by targeted RNA-seq.Cell proliferation, derived from the mean expression of 10 proliferation-associated genes (namely BUB1, CCNB2, CDK1, CDKN3, FOXM1, KIAA0101, MAD2L1, MELK, MKI67, and TOP2A), was identified as a marker of response to ICIs in NSCLC. Poorly, moderately, and highly proliferative tumors were somewhat equally represented in NSCLC, with tumors with the highest PD-L1 expression being more frequently moderately proliferative as compared to lesser levels of PD-L1 expression. Proliferation status had an impact on survival in patients with both PD-L1 positive and negative tumors. There was a significant survival advantage for moderately proliferative tumors compared to their combined highly/poorly counterparts (p = 0.021). Moderately proliferative PD-L1 positive tumors had a median survival of 14.6 months that was almost twice that of PD-L1 negative highly/poorly proliferative at 7.6 months (p = 0.028). Median survival in moderately proliferative PD-L1 negative tumors at 12.6 months was comparable to that of highly/poorly proliferative PD-L1 positive tumors at 11.5 months, but in both instances less than that of moderately proliferative PD-L1 positive tumors. Similar to survival, proliferation status has impact on disease control (DC) in patients with both PD-L1 positive and negative tumors. Patients with moderately versus those with poorly or highly proliferative tumors have a superior DC rate when combined with any classification schema used to score PD-L1 as a positive result (i.e., TPS ≥ 50% or ≥ 1%), and best displayed by a DC rate for moderately proliferative tumors of no less than 40% for any classification of PD-L1 as a negative result. While there is an over representation of moderately proliferative tumors as PD-L1 expression increases this does not account for the improved survival or higher disease control rates seen in PD-L1 negative tumors.Cell proliferation is potentially a new biomarker of response to ICIs in NSCLC and is applicable to PD-L1 negative tumors." @default.
• W2922140624 created "2019-03-22" @default.
• W2922140624 creator A5000632212 @default.
• W2922140624 creator A5002809073 @default.
• W2922140624 creator A5009400324 @default.
• W2922140624 creator A5009728559 @default.
• W2922140624 creator A5010848117 @default.
• W2922140624 creator A5013254368 @default.
• W2922140624 creator A5017213600 @default.
• W2922140624 creator A5021930725 @default.
• W2922140624 creator A5025646273 @default.
• W2922140624 creator A5027499943 @default.
• W2922140624 creator A5029533127 @default.
• W2922140624 creator A5030163974 @default.
• W2922140624 creator A5031994882 @default.
• W2922140624 creator A5033510051 @default.
• W2922140624 creator A5036160211 @default.
• W2922140624 creator A5036389865 @default.
• W2922140624 creator A5036913210 @default.
• W2922140624 creator A5037475520 @default.
• W2922140624 creator A5040346750 @default.
• W2922140624 creator A5040432994 @default.
• W2922140624 creator A5040874105 @default.
• W2922140624 creator A5043593421 @default.
• W2922140624 creator A5044045808 @default.
• W2922140624 creator A5044114322 @default.
• W2922140624 creator A5048078683 @default.
• W2922140624 creator A5049142712 @default.
• W2922140624 creator A5051789976 @default.
• W2922140624 creator A5052728393 @default.
• W2922140624 creator A5053481267 @default.
• W2922140624 creator A5059394561 @default.
• W2922140624 creator A5060424549 @default.
• W2922140624 creator A5063874520 @default.
• W2922140624 creator A5064172667 @default.
• W2922140624 creator A5067217729 @default.
• W2922140624 creator A5071349192 @default.
• W2922140624 creator A5071827163 @default.
• W2922140624 creator A5072247678 @default.
• W2922140624 creator A5074947833 @default.
• W2922140624 creator A5076315759 @default.
• W2922140624 creator A5079166812 @default.
• W2922140624 creator A5083509294 @default.
• W2922140624 creator A5086168886 @default.
• W2922140624 creator A5086887734 @default.
• W2922140624 creator A5087584832 @default.
• W2922140624 creator A5089516753 @default.
• W2922140624 creator A5090732009 @default.
• W2922140624 date "2019-02-01" @default.
• W2922140624 modified "2023-10-10" @default.
• W2922140624 title "Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients" @default.
• W2922140624 cites W1982488143 @default.
• W2922140624 cites W2039161031 @default.
• W2922140624 cites W2104347254 @default.
• W2922140624 cites W2293531514 @default.
• W2922140624 cites W2368001341 @default.
• W2922140624 cites W2409327223 @default.
• W2922140624 cites W2412051818 @default.
• W2922140624 cites W2539702506 @default.
• W2922140624 cites W2559602085 @default.
• W2922140624 cites W2560367415 @default.
• W2922140624 cites W2572174216 @default.
• W2922140624 cites W2604733544 @default.
• W2922140624 cites W2725398806 @default.
• W2922140624 cites W2750667003 @default.
• W2922140624 cites W2765696340 @default.
• W2922140624 cites W2766865369 @default.
• W2922140624 cites W2767600184 @default.
• W2922140624 cites W2796207838 @default.
• W2922140624 cites W2806277324 @default.
• W2922140624 cites W2810330658 @default.
• W2922140624 cites W2886320197 @default.
• W2922140624 cites W2892164007 @default.
• W2922140624 doi "https://doi.org/10.1186/s40425-019-0506-3" @default.
• W2922140624 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6359802" @default.
• W2922140624 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30709424" @default.
• W2922140624 hasPublicationYear "2019" @default.
• W2922140624 type Work @default.
• W2922140624 sameAs 2922140624 @default.
• W2922140624 citedByCount "56" @default.
• W2922140624 countsByYear W29221406242019 @default.
• W2922140624 countsByYear W29221406242020 @default.
• W2922140624 countsByYear W29221406242021 @default.
• W2922140624 countsByYear W29221406242022 @default.
• W2922140624 countsByYear W29221406242023 @default.
• W2922140624 crossrefType "journal-article" @default.
• W2922140624 hasAuthorship W2922140624A5000632212 @default.
• W2922140624 hasAuthorship W2922140624A5002809073 @default.
• W2922140624 hasAuthorship W2922140624A5009400324 @default.
• W2922140624 hasAuthorship W2922140624A5009728559 @default.
• W2922140624 hasAuthorship W2922140624A5010848117 @default.
• W2922140624 hasAuthorship W2922140624A5013254368 @default.
• W2922140624 hasAuthorship W2922140624A5017213600 @default.
• W2922140624 hasAuthorship W2922140624A5021930725 @default.
• W2922140624 hasAuthorship W2922140624A5025646273 @default.
• W2922140624 hasAuthorship W2922140624A5027499943 @default.
• W2922140624 hasAuthorship W2922140624A5029533127 @default.
• W2922140624 hasAuthorship W2922140624A5030163974 @default.
• W2922140624 hasAuthorship W2922140624A5031994882 @default.
• W2922140624 hasAuthorship W2922140624A5033510051 @default.

• next